Navigation Links
Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
Date:7/7/2008

tiny array of LEDs.

In the Litx BPH application, a modified standard urethral catheter positions the proprietary light-emitting LED array precisely within the prostate. After systemic injection of LS11, the LEDs are turned on, and activation of the drug occurs locally within the prostate. When the short treatment is complete, the LED-containing catheter is removed and thrown away. The goal of the therapy is to kill prostate tissue via apoptosis within a highly localized zone in the prostate, without causing inflammation. The short, single outpatient treatment is designed to effectively re-establish and maintain an unobstructed urine flow, relieving BPH symptoms.

ABOUT LIGHT SCIENCES ONCOLOGY

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)) to provide safer and more effective treatment for cancer and other conditions. In addition to the Phase III trials in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the Company has completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened the scope of potential therapeutic applications of the versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease and dermatology. The Company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.

Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light Sciences Oncology, Inc.

Contact:

Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer

425-957-8900

bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.

President and CEO

425-957-8900

dr_llew@lsoncolo
'/>"/>

SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
2. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
3. New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
4. Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
5. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
6. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
9. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
10. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...tage A of Trial Assessing Regimen of Bavituxima..., TUSTIN, Calif., Oct. 7 /..., a clinical stage biopharmaceutical,company devel...ancer and,hepatitis C virus (HCV) infection, today... first stage of a Phase II trial of bavituximab in...
(Date:10/6/2008)...ollege of Gastroenterology Annual ...Newswire/ -- Combined results from two Phase 3,stu...terology Annual,Scientific Meeting (ACG) in Orland...igher healing rates than lansoprazole among patien...(EE). TAK-390MR combines,dexlansoprazole with a Du...
(Date:10/6/2008)...te to Improve Patient Safety, WASHINGTON, Oct. 6 ...,Cardiology in collaboration with the American Col...sociation today released consensus guidelines,outl... ulcers and,gastrointestinal (GI) bleeding among p... (NSAIDs) along with antiplatelet agents., Gastro...
(Date:10/6/2008).... 6 /- Complete,Genomics Inc., a newl...ng,company, and the Institute for Systems Biology ... populationwide human genome studies., In phase o...proprietary,DNA sequencing technology to sequence ...nce proof-of-concept has been demonstrated, ISB an...
Breaking Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 1125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 3125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 4Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 1Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 3Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 1New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 2New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 3New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 5New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 6New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 7LUMEDX Updates Real Time Patient and Resource Scheduler for Healthcare Systems 4095 1LUMEDX Updates Real Time Patient and Resource Scheduler for Healthcare Systems 4095 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 -...ompany focused on,the discovery and development of... findings from its novel human-in-mouse (HIM) tiss...uccessfully created,invasive human tumors that dev...issue. This model enables scientists, for the firs...
...INESS WIRE)--Apr 19, 2007 - Antares Pharma, Inc.,(...tly completed,site application study demonstrating...mal gel, was absorbed on a bioequivalent,basis aft...in site,locations., The study was an open-label, c...harmacokinetic study. The trial enrolled 25,health...
Other Medicine Technology:Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 2Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
... the Vanderbilt University say that constant expos...mal development of premature babies' biological// ... Research. The researchers found that the lighting...aster biological clock in the babies. Earlier res...
...ain-crushing headache, you are probably better off...owing the regulatory doses of aspirin, according//...The study found that salicylic acid, the active in...rtain Indian spices like cumin, turmeric and papri...
...ive at Martin Luther King Jr./Drew Medical Center ...n, it will endeavor to get back the accreditation ...rauma care. Antionette Smith Epps, chief executi...of the new leadership team that is determined to i...
...annual back-to-school survey on teens' attitudes t...arents clueless about children’s immoral practices...ded parties where alcohol or illegal drugs were us...It doesn’t imply that parents were aware of what w...
Other Medicine News:Health News:Parents ignorant about kids' immoral practices 2
Cholesterol/HDL Standard 50 mg/dl.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma.
Medicine Products: